Study Plan: There are 3 dose escalation groups. Sequentially enrolled subjects will be assigned to the dosage level being evaluated at the time of enrollment. All injections will be administered intramuscularly (IM) by needle and syringe. Cumulative safety data will be reviewed weekly by a Protocol Safety Review Team (PSRT) that includes an Independent Safety Monitor (ISM) while injections are being administered. Safety, including reactogenicity and unsolicited AEs, laboratory findings, pharmacokinetics, and VRC07 antibody levels in blood will be assessed after the injection and summarized for an interim analysis at 4 weeks post injection. The second subject in each dose group will be injected after the 4 weeks safety assessment for the first subject. Decisions regarding dose escalation and subject enrollments will be based on safety data and the VRC07 concentration in blood at 4 weeks after product administration. The pharmacokinetics of VRC07 at each dose level will be evaluated to determine the dose that would result in antibody production that achieves at least 50 mcg/mL VRC07 concentration in serum at 4 weeks post injection with a target set point of more than or equal to 5 mcg/mL at 12 weeks post injection.